Advertisement

Amino Acids

, Volume 40, Issue 4, pp 1195–1204 | Cite as

Structural and functional insights into polymorphic enzymes of cytochrome P450 2C8

  • Hualin Jiang
  • Fangfang Zhong
  • Lu Sun
  • Weiyue Feng
  • Zhong-Xian Huang
  • Xiangshi TanEmail author
Original Article

Abstract

The cytochrome P450 (CYP) superfamily plays a key role in the oxidative metabolism of a wide range of drugs and exogenous chemicals. CYP2C8 is the principal enzyme responsible for the metabolism of the anti-cancer drug paclitaxel in the human liver. Nearly all previous works about polymorphic variants of CYP2C8 were focused on unpurified proteins, either cells or human liver microsomes; therefore their structure–function relationships were unclear. In this study, two polymorphic enzymes of CYP2C8 (CYP2C8.4 (I264M) and CYP2C8 P404A) were expressed in E. coli and purified. Metabolic activities of paclitaxel by the two purified polymorphic enzymes were observed. The activity of CYP2C8.4 was 25% and CYP2C8 P404A was 30% of that of WT CYP2C8, respectively. Their structure–function relationships were systematically investigated for the first time. Paclitaxel binding ability of CYP2C8.4 increased about two times while CYP2C8 P404A decreased about two times than that of WT CYP2C8. The two polymorphic mutant sites of I264 and P404, located far from active site and substrate binding sites, significantly affect heme and/or substrate binding. This study indicated that two important nonsubstrate recognition site (SRS) residues of CYP2C8 are closely related to heme binding and/or substrate binding. This discovery could be valuable for explaining clinically individual differences in the metabolism of drugs and provides instructed information for individualized medication.

Keywords

Structure–function relationship Polymorphism CYP2C8 Drug metabolism Individualized medication 

Notes

Acknowledgments

We thank Prof. E.F. Johnson (The Scripps Research Institute, California, USA) for the generous gift of the pCWOri + plasmid, encoding CYP 2C8dH and Prof. J.M. Chen (Fudan University, Shanghai, China) for the generous support of paclitaxel. This work is supported in part by Shanghai Pujiang Talent Project (08PJ14017), the National Science Foundation of China (20771029), the Shanghai Leading Academic Discipline Project (B108), the Program for the Platform of new medicine creation (NO. 2009ZX09301-011), the Specialized Research Fund for the Doctoral Program of Higher Education, and Beijing Synchrotron Radiation Facility (BSRF) in the Institute of High Energy Physics, Chinese Academy of Sciences.

Supplementary material

726_2010_743_MOESM1_ESM.tif (55 kb)
SF1. UV/Vis spectra of the ferrous-CO states of WT CYP2C8 and its variants. Spectra were recorded in 50 mM KPi, 500 mM NaCl, and 20% glycerol buffer, pH 7.4 at 25°C, proteins concentration were 5 μM (TIFF 54 kb)
726_2010_743_MOESM2_ESM.tif (491 kb)
SF2. Stopped-flow kinetics of electron transfer of WT CYP2C8 and its variants when reduced by Na2S2O4 (TIFF 490 kb)
726_2010_743_MOESM3_ESM.tif (456 kb)
SF3. Reversed-phase HPLC of paclitaxel and its metabolite. (A) There was no NADPH in the reaction system. (B) Reaction started by the addition of NADPH. Conditions: see experimental section (TIFF 455 kb)
726_2010_743_MOESM4_ESM.tif (491 kb)
(TIFF 490 kb)
726_2010_743_MOESM5_ESM.tif (92 kb)
SF4. The mass spectra of a band (paclitaxel) from the positive-ion MS analysis (TIFF 92 kb)
726_2010_743_MOESM6_ESM.tif (84 kb)
SF5. The mass spectra of b band (6α-OH-paclitaxel) from the positive-ion MS analysis (TIFF 84 kb)
726_2010_743_MOESM7_ESM.tif (491 kb)
SF6. Eadie-Hofstee plot of paclitaxel α-hydroxylation by WT CYP2C8 and its variants. The solid line indicates fitting of data to the Eadie-Hofstee equation by linear regression (TIFF 490 kb)

References

  1. Andersson LA, Peterson JA (1995) Active-site analysis of ferric P450 enzymes: hydrogen-bonding effects on the circular dichroism spectra. Biochem Biophys Res Commun 211:389–395PubMedCrossRefGoogle Scholar
  2. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64:1579–1589PubMedCrossRefGoogle Scholar
  3. Berry EA, Trumpower BL (1987) Simultaneous determination of hemes a, b, and c from pyridine hemochrome spectra. Anal Biochem 161:1–15PubMedCrossRefGoogle Scholar
  4. Chen CD, Doray B, Kemper B (1997) Efficient assembly of functional cytochrome P450 2C2 requires a spacer sequence between the N-terminal signal anchor and catalytic domains. J Biol Chem 272:22891–22897PubMedCrossRefGoogle Scholar
  5. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, Goldstein JA (2001) Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11:597–607PubMedCrossRefGoogle Scholar
  6. Dawson JH, Andersson LA, Sono M (1982) Spectroscopic investigations of ferric cytochrome P-450-CAM ligand complexes. Identification of the ligand trans to cysteinate in the native enzyme. J Biol Chem 257:3606–3617PubMedGoogle Scholar
  7. Denisov IG, Makris TM, Sligar SG, Schlichting I (2005) Structure and chemistry of cytochrome P450. Chem Rev 105:2253–2277PubMedCrossRefGoogle Scholar
  8. Dickmann LJ, Locuson CW, Jones JP, Rettie AE (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 65:842–850PubMedCrossRefGoogle Scholar
  9. Estabrook RW, Werringloer J (1978) The measurement of difference spectra: application to the cytochromes of microsomes. Methods Enzymol 52:212–220PubMedCrossRefGoogle Scholar
  10. Hanioka N, Matsumoto K, Saito Y, Narimatsu S (2010) Functional characterization of CYP2C8.13 and CYP2C8.14: catalytic activities toward paclitaxel. Basic Clin Pharmacol Toxicol. doi: 10.1111/j.1742-7843.2010.00543.x PubMedGoogle Scholar
  11. Haugen DA, Coon MJ (1976) Properties of electrophoretically homogeneous phenobarbital-inducible and beta-naphthoflavone-inducible forms of liver microsomal cytochrome P-450. J Biol Chem 251:7929–7939PubMedGoogle Scholar
  12. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, Matsushima E, Uchiyama S, Tokunaga H, Kimura H, Minami N, Katoh M, Sugai K, Goto Y, Tamura T, Yamamoto N, Ohe Y, Kunitoh H, Nokihara H, Yoshida T, Minami H, Saijo N, Ando M, Ozawa S, Saito Y, Sawada J (2005) Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383 N, found in a Japanese population. Drug Metab Dispos 33:630–636PubMedCrossRefGoogle Scholar
  13. Hlavica P (2006) Functional interaction of nitrogenous organic bases with cytochrome P450: a critical assessment and update of substrate features and predicted key active-site elements steering the access, binding, and orientation of amines. Biochim Biophys Acta 1764:645–670PubMedGoogle Scholar
  14. Ishikawa C, Ozaki H, Nakajima T, Ishii T, Kanai S, Anjo S, Shirai K, Inoue I (2004) A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin. J Hum Genet 49:582–585PubMedCrossRefGoogle Scholar
  15. Jefcoate CR (1978) Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol 52:258–279PubMedCrossRefGoogle Scholar
  16. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 47:1969–1979PubMedCrossRefGoogle Scholar
  17. Koo LS, Tschirret-Guth RA, Straub WE, Moenne-Loccoz P, Loehr TM, Ortiz de Montellano PR (2000) The active site of the thermophilic CYP119 from Sulfolobus solfataricus. J Biol Chem 275:14112–14123PubMedCrossRefGoogle Scholar
  18. Koo LS, Immoos CE, Cohen MS, Farmer PJ, Ortiz de Montellano PR (2002) Enhanced electron transfer and lauric acid hydroxylation by site-directed mutagenesis of CYP119. J Am Chem Soc 124:5684–5691PubMedCrossRefGoogle Scholar
  19. Krone N, Riepe FG, Grotzinger J, Partsch CJ, Bramswig J, Sippell WG (2005) The residue E351 is essential for the activity of human 21-hydroxylase: evidence from a naturally occurring novel point mutation compared with artificial mutants generated by single amino acid substitutions. J Mol Med 83:561–568PubMedCrossRefGoogle Scholar
  20. Kumar GN, Oatis JE Jr, Thornburg KR, Heldrich FJ, Hazard ES 3rd, Walle T (1994) 6 alpha-Hydroxytaxol: isolation and identification of the major metabolite of taxol in human liver microsomes. Drug Metab Dispos 22:177–179PubMedGoogle Scholar
  21. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105–132PubMedCrossRefGoogle Scholar
  22. Lee VH, Sporty JL, Fandy TE (2001) Pharmacogenomics of drug transporters: the next drug delivery challenge. Adv Drug Deliv Rev 50 (Suppl 1):S33–S40CrossRefGoogle Scholar
  23. Martinis SA, Blanke SR, Hager LP, Sligar SG, Hoa GH, Rux JJ, Dawson JH (1996) Probing the heme iron coordination structure of pressure-induced cytochrome P420cam. Biochemistry 35:14530–14536PubMedCrossRefGoogle Scholar
  24. McLean MA, Maves SA, Weiss KE, Krepich S, Sligar SG (1998) Characterization of a cytochrome P450 from the acidothermophilic archaea Sulfolobus solfataricus. Biochem Biophys Res Commun 252:166–172PubMedCrossRefGoogle Scholar
  25. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 28:1303–1310PubMedGoogle Scholar
  26. Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370–2378PubMedGoogle Scholar
  27. Plasilova M, Stoilov I, Sarfarazi M, Kadasi L, Ferakova E, Ferak V (1999) Identification of a single ancestral CYP1B1 mutation in Slovak Gypsies (Roms) affected with primary congenital glaucoma. J Med Genet 36:290–294PubMedGoogle Scholar
  28. Pontius J, Richelle J, Wodak SJ (1996) Deviations from standard atomic volumes as a quality measure for protein crystal structures. J Mol Biol 264:121–136PubMedCrossRefGoogle Scholar
  29. Poon GK, Wade J, Bloomer J, Clarke SE, Maltas J (1996) Rapid screening of taxol metabolites in human microsomes by liquid chromatography/electrospray ionization-mass spectrometry. Rapid Commun Mass Spectrom 10:1165–1168PubMedCrossRefGoogle Scholar
  30. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW (1994) Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54:5543–5546PubMedGoogle Scholar
  31. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413–580PubMedCrossRefGoogle Scholar
  32. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinski CJ, Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87–96PubMedCrossRefGoogle Scholar
  33. Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK (2010) Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 38:1261–1266PubMedCrossRefGoogle Scholar
  34. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF (2004) Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J Biol Chem 279:9497–9503PubMedCrossRefGoogle Scholar
  35. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227–17237PubMedCrossRefGoogle Scholar
  36. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–423PubMedGoogle Scholar
  37. Singh R, Ting JG, Pan Y, Teh LK, Ismail R, Ong CE (2008) Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet 23:165–174PubMedCrossRefGoogle Scholar
  38. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566–575PubMedGoogle Scholar
  39. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, Ishida S, Sai K, Ozawa S, Sawada JI (2001) Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 24:1427–1430PubMedCrossRefGoogle Scholar
  40. Soyama A, Hanioka N, Saito Y, Murayama N, Ando M, Ozawa S, Sawada J (2002) Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol 91:174–178PubMedCrossRefGoogle Scholar
  41. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, Brice G, Aktan SG, Chevrette L, Coca-Prados M, Sarfarazi M (1998) Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet 62:573–584PubMedCrossRefGoogle Scholar
  42. Sun L, Wang ZH, Ni FY, Tan XS, Huang ZX (2009) The role of Ile476 in the structural stability and substrate binding of human cytochrome P450 2C8. Protein J. doi: 10.1007/s10930-009-9218-8 Google Scholar
  43. Tian WD, Wells AV, Champion PM, Di Primo C, Gerber N, Sligar SG (1995) Measurements of CO geminate recombination in cytochromes P450 and P420. J Biol Chem 270:8673–8679PubMedCrossRefGoogle Scholar
  44. Totah RA, Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 77:341–352PubMedCrossRefGoogle Scholar
  45. Udit AK, Hagen KD, Goldman PJ, Star A, Gillan JM, Gray HB, Hill MG (2006) Spectroscopy and electrochemistry of cytochrome P450 BM3-surfactant film assemblies. J Am Chem Soc 128:10320–10325PubMedCrossRefGoogle Scholar
  46. Wang HP, Kimura T (1976) Purification and characterization of adrenal cortex mitochondrial cytochrome P-450 specific for cholesterol side chain cleavage activity. J Biol Chem 251:6068–6074PubMedGoogle Scholar
  47. Wester MR, Stout CD, Johnson EF (2002) Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. Methods Enzymol 357:73–79PubMedCrossRefGoogle Scholar
  48. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 279:35630–35637PubMedCrossRefGoogle Scholar
  49. Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T (1999) Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27:1260–1266PubMedGoogle Scholar
  50. Yasar U, Bennet AM, Eliasson E, Lundgren S, Wiman B, De Faire U, Rane A (2003) Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 13:715–720PubMedCrossRefGoogle Scholar
  51. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416–423Google Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Hualin Jiang
    • 1
  • Fangfang Zhong
    • 1
  • Lu Sun
    • 1
  • Weiyue Feng
    • 2
  • Zhong-Xian Huang
    • 1
  • Xiangshi Tan
    • 1
    Email author
  1. 1.Department of Chemistry and Institutes of Biomedical SciencesFudan UniversityShanghaiChina
  2. 2.Institute of High Energy PhysicsChinese Academy of SciencesBeijingChina

Personalised recommendations